TITLE

Homeostatic regulation of zinc transporters in the human small intestine by dietary zinc supplementation

AUTHOR(S)
Crogg, R. A.; Phillips, S. R.; Piper, J. M.; Varma, J. S.; Campbell, F. C.; Mathers, J. C.; Ford, D.
PUB. DATE
April 2005
SOURCE
Gut;Apr2005, Vol. 54 Issue 4, p469
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: The role of intestinal transporter regulation in optimising nutrient absorption has been studied extensively in rodent and cell line models but not in human subjects. Aims: The aim of the present study was to investigate the response in vivo of zinc transporters in the human enterocyte to dietary zinc supplementation. Subjects: Eighteen patients who had previously undergone ileostomy, all free of any symptoms of inflammatory bowel disease. Methods: Subjects took a daily zinc supplement of 25 mg for 14 days in a double blind, placebo controlled, crossover trial. The effect of the supplement on expression in ileal biopsies of the zinc transporters SLC30A1, 51C30A4, 51C30A5, SLC39A1, SLC39A4, and metallothionein was measured by reverse transcription-polymerase chain reaction RT-PCR. Expression of SLC30A1, SLC30A5, and SLC39A4 was also examined by immunoblotting. Results: The zinc supplement reduced SLC30A1 mRNA (1-4-fold) together with SLC30A1, SLC30A5, and 5LC39A4 protein (1.8-fold, 3.7-fold, and to undetectable levels, respectively) in ileal mucosa and increased metallothionein mRNA (1.7-fold). The supplement had no effect on expression of SLC30A4 or SLC39A1 mRNA. Localisation of SLC30A5 at the apical human enterocyte/colonocyte membrane and also at the apical membrane of Caco-2 cells was demonstrated by immunohistochemistry. Commensurate with these observations in zinc supplemented human subjects, SLC30A1, SLC30A5, and 51C39A4 mRNA and protein were reduced in Caco-2 cells cultured at 200 μM compared with 100 pM zinc. Conclusions: These observations indicate that, in response to variations in dietary zinc intakes, regulated expression of plasma membrane zinc transporters in the human intestine contributes to maintenance of zinc status.
ACCESSION #
16556649

 

Related Articles

  • Interleukin-18 is increased only in a minority of patients with active Crohn’s disease. Schmidt, C.; Giese, T.; Goebel, R.; Schilling, M.; Marth, T.; Ruether, A.; Schreiber, S.; Zeuzem, S.; Meuer, S.; Stallmach, A. // International Journal of Colorectal Disease;Sep2007, Vol. 22 Issue 9, p1013 

    It has been suggested that Crohn’s Disease (CD) is associated with an elevated T helper 1 response as manifested by increased production of interleukin-18 (IL-18). Local concentrations of neutralizing IL-18 binding proteins (IL-18bp) may counteract biological functions of mature IL-18 in...

  • Association of a Functional Variant in the Wnt Co-Receptor LRP6 with Early Onset Ileal Crohn's Disease. Koslowski, Maureen J.; Teltschik, Zora; Beisner, Julia; Schaeffeler, Elke; Guoxing Wang; Kübler, Irmgard; Gersemann, Michael; Cooney, Rachel; Jewell, Derek; Reinisch, Walter; Vermeire, Séverine; Rutgeerts, Paul; Schwab, Matthias; Stange, Eduard F.; Wehkamp, Jan // PLoS Genetics;Feb2012, Vol. 8 Issue 2, Special section p1 

    Ileal Crohn's Disease (CD), a chronic small intestinal inflammatory disorder, is characterized by reduced levels of the antimicrobial peptides DEFA5 (HD-5) and DEFA6 (HD-6). Both of these α-defensins are exclusively produced in Paneth cells (PCs) at small intestinal crypt bases. Different...

  • Celgene Pays US$710 M Upfront to License Nogra Pharma's Phase III-Ready GED-0301. Cartwright, Heather // PharmaDeals Review;2014, Vol. 2014 Issue 5, p23 

    In return for a record-breaking US$710 M upfront fee, Celgene has licensed global rights to develop and commercialise Nogra Pharma's GED-0301, an oral antisense DNA oligonucleotide targeting Smad7 mRNA that has completed a Phase II trial in patients with active Crohn's disease. Data from the...

  • Protection of epithelial barrier function by the Crohn's disease associated gene protein tyrosine phosphatase N2.  // Inflammatory Bowel Disease Monitor;2010, Vol. 10 Issue 4, p139 

    The protein tyrosine-phosphatase non-receptor type 2 (PTPN2) gene is associated with Crohn's disease. In this functional study, a role for PTPN2 in intestinal epithelial barrier function is described. PTPN2 mRNA expression was increased in the terminal ileum and colon of patients with active...

  • 6-MERCAPTOPURINE FOR THE MANAGEMENT OF ULCERATIVE COLITIS: A CONCEPT WHOSE TIME HAS COME. Peppercorn, Mark A. // American Journal of Gastroenterology;Sep1996, Vol. 91 Issue 9, p1689 

    Comments on several researches concerning the role of 6-mercaptopurine (6-MP) in the management of ulcerative colitis. Benefits of 6-MP for patients of Crohn's disease; Reasons for the reluctance of patients in using 6-MP for the management of ulcerative colitis; Comparison of the risks...

  • Factors Associated with the Development of Intestinal Strictures or Obstructions in Patients with Crohn's Disease. Lichtenstein, Gary R.; Olson, Allan; Travers, Suzanne; Diamond, Robert H.; Chen, Donny M.; Pritchard, Michelle L.; Feagan, Brian G.; Cohen, Russell D.; Salzberg, Bruce A.; Hanauer, Stephen B.; Sandborn, William J. // American Journal of Gastroenterology;May2006, Vol. 101 Issue 5, p1030 

    OBJECTIVE: Theoretical concern exists that rapid luminal healing in Crohn's disease (CD) with therapies like infliximab increases the risk of intestinal stenosis, stricture, or obstruction (SSOs). METHODS: Data were analyzed from the ongoing observational TREAT (the Crohn's Therapy, Resource,...

  • A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease. Lichtenstein, Gary R; Rutgeerts, Paul; Sandborn, William J; Sands, Bruce E; Diamond, Robert H; Blank, Marion; Montello, Jennifer; Tang, Linda; Cornillie, Freddy; Colombel, Jean-Frédéric // American Journal of Gastroenterology;Jul2012, Vol. 107 Issue 7, p1051 

    OBJECTIVES:The objective of this study was to analyze the safety of long-term infliximab treatment, with/without concomitant immunomodulators, across Crohn's disease (CD) and ulcerative colitis (UC) clinical trials.METHODS:To maximize sample size, we pooled primary safety data across 10 CD or UC...

  • Anorectal Crohn's Disease: Surgical and Medical Management. Aronoff, J.S.; Korelitz, B.I.; Sohn, N.; Ky, A.; Rajapakse, R.; Weinstein, M.A.; Cohen, F.S. // BioDrugs;2000, Vol. 13 Issue 2, p95 

    In some patients with Crohn's disease the anorectal complications are the major cause of symptoms and morbidity. Anorectal Crohn's disease may be present in patients with intestinal Crohn's disease, may be the initial manifestation of the disease, or rarely occurs without involvement of Crohn's...

  • Increased Intestinal Permeability in Patients with Crohn's Disease and Their Relatives. Hollander, Daniel; Vadheim, Constance M.; Brettholz, Edward; Pettersen, Gloria M.; Delahunty, Thomas; Rotter, Jerome I. // Annals of Internal Medicine;Dec86, Vol. 105 Issue 6, p883 

    Presents a study that examined the role of increase intestinal permeability in patients with Crohn's disease. Causes of Crohn's disease; Methodology of the study; Discussion on the result of the study.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics